Algernon Pharmaceuticals Inc. (AGNPF)
- Previous Close
0.0539 - Open
0.0670 - Bid 0.0490 x --
- Ask 0.0670 x --
- Day's Range
0.0539 - 0.0670 - 52 Week Range
0.0375 - 0.1230 - Volume
15,012 - Avg. Volume
7,376 - Market Cap (intraday)
1.61M - Beta (5Y Monthly) 1.83
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
algernonpharmaceuticals.comRecent News: AGNPF
View More
Performance Overview: AGNPF
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AGNPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AGNPF
View MoreValuation Measures
Market Cap
1.58M
Enterprise Value
1.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.24
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.42%
Return on Equity (ttm)
-25.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-362.49k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
357.92k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.28M